Descovy Tablet
NDC Package 61958-2002-2
Package Information
Descovy (emtricitabine and tenofovir alafenamide) tablets is a medication used with other HIV medications to help control HIV infection. This formulation utilizes a tablet delivery system. Marketed by Gilead Sciences, Inc., this product is identified by NDC 61958-2002 and is authorized under FDA application NDA208215.
Identification & Billing
- RxCUI: 1747691 - emtricitabine 200 MG / tenofovir alafenamide 25 MG Oral Tablet
- RxCUI: 1747697 - Descovy 200 MG / 25 MG Oral Tablet
- RxCUI: 1747697 - emtricitabine 200 MG / tenofovir alafenamide 25 MG Oral Tablet [Descovy]
- RxCUI: 1747697 - Descovy (emtricitabine 200 MG / tenofovir alafenamide 25 MG) Oral Tablet
- RxCUI: 2590641 - emtricitabine 120 MG / tenofovir alafenamide 15 MG Oral Tablet
Clinical Specifications
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Nucleoside Reverse Transcriptase Inhibitors - [MoA] (Mechanism of Action)
- Nucleosides - [CS]
Regulatory & Marketing
Hierarchy Structure
- 61958 - Gilead Sciences, Inc.
- 61958-2002 - Descovy
- 61958-2002-2 - 30 TABLET in 1 BLISTER PACK
- 61958-2002 - Descovy
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (61958-2002). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 61958-2002-2 identifies a specific commercial package of 30 tablet in 1 blister pack of Descovy, a human prescription drug labeled by Gilead Sciences, Inc.. This tablet is formulated for oral use and contains emtricitabine; tenofovir alafenamide fumarate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gilead Sciences, Inc. on April 04, 2016. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: emtricitabine and tenofovir alafenamide. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. They are often called NRTIs. This product should not be used by itself to help control HIV infection. Doing so can make your treatment less effective. Use combination treatment with at least one other HIV medication. This product is also approved in the US to help prevent HIV infection in people who have a high risk for infection. Some things that increase risk include having a partner infected with HIV, having unprotected sex, having multiple sex partners, infection with a sexually transmitted disease-STD, or use/abuse of drugs or alcohol. Emtricitabine/tenofovir alafenamide is not a cure for HIV infection. Also, it will not always prevent HIV infection. To help prevent becoming infected with HIV and to decrease your risk of spreading HIV disease to others, do all of the following: (1) continue to take all HIV medications exactly as prescribed by your doctor, (2) always use an effective barrier method (latex or polyurethane condoms/dental dams) during all sexual activity, and (3) do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.
How is this Gilead Sciences, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 61958200202. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.